Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Time of day does not affect TAVR or SAVR outcomes

One previous study had suggested outcomes may improve in the afternoon, but researchers did not find that to be the case. 

TAVR is safe and effective among asymptomatic patients, new research confirms

TAVR was associated with a consistently low risk of all-cause mortality or disabling stroke.

Both younger and elderly heart failure patients benefit from TEER

Researchers used data from the COAPT trial to examine TEER's impact on patients from different age groups. 

Thumbnail

Sapien 3 Ultra THV outperforms its predecessor, reducing PVL after TAVR procedures

The risk of all-cause mortality, stroke, major bleeding events or permanent pacemaker implantation was similar between the two valves.

Performing TAVR and TMVR during the same hospitalization may provide value

Patients undergoing both procedures at once tended to be sicker, but their risk of poor outcomes did not significantly increase. 

Thumbnail

Adjusting implantation technique during TAVR reduces risk of permanent pacemakers

Researchers emphasized that permanent pacemakers are “one of the most feared complications" associated with TAVR. 

Thumbnail

Hydra THV associated with promising TAVR outcomes after 1 year

Researchers reported "significant improvements" in patients after one year. 

LAAC or DOACs? How treatment strategies for AFib impact long-term outcomes

The new analysis provided an update on data from the PRAGUE-17 trial. 

Displaying 497 - 504 of 879
Design by Adaptive Theme